Literature DB >> 33140580

The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.

Krisstina Gowin1, Blake T Langlais2, Heidi E Kosiorek2, Amylou Dueck2, Denise Millstine3, Jennifer Huberty4, Ryan Eckert5, Ruben A Mesa5.   

Abstract

Myeloproliferative neoplasms (MPNs) are characterized by significant symptom burden. Integrative medicine (IM) offers unique symptom management strategies. This study describes IM interventions utilized by MPN patients and the association with symptom burden, quality of life, depression, and fatigue adjusted for lifestyle confounders. MPN patients were surveyed online for IM utilization, MPN symptom burden (MPN-Symptom Assessment Form Total Symptom Score), depression (Patient Health Questionnaire), fatigue (Brief Fatigue Inventory), and a single question on overall quality of life. Measures were compared by IM participation and adjusted for alcohol and tobacco use, BMI, diet, and MPN type using multiple linear and logistic regression. A total of 858 participants were included in the analysis. Aerobic activity (p =< 0.001) and strength training (p = 0.01) were associated with lower mean symptom burden while massage (p =< 0.001) and support groups (p =< 0.001) were associated with higher levels of symptom burden. Higher quality of life was reported in massage (p = 0.04) and support groups (p = 0.002) while lower quality of life was noted in aerobic activity (p =< 0.001) and strength training (p = 0.001). A lower depression screening score was noted in those participating in aerobic activity (p = 0.006), yoga (p = 0.03), and strength training (p = 0.02). Lower fatigue was noted in those participating in aerobic activity (p =< 0.001) and strength training (p = 0.03) while higher fatigue was noted in those participating in massage (p =< 0.001) and breathing techniques (p = 0.02). Data available on request from the authors. This international survey of MPN patients on IM usage, has shown that patients who participated in a form of IM had a pattern of decreased levels of symptom burden, fatigue, depression, and higher QoL, as adjusted for health lifestyle practices overall.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  essential thrombocytosis; integrative medicine; lifestyle; myelofibrosis; myeloproliferative neoplasms; polycythemia vera; quality of life

Mesh:

Year:  2020        PMID: 33140580      PMCID: PMC7774715          DOI: 10.1002/cam4.3566

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  26 in total

Review 1.  Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Authors:  Ruben A Mesa; Robyn M Scherber; Holly L Geyer
Journal:  Leuk Lymphoma       Date:  2015-03-17

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 3.  Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-12       Impact factor: 10.047

4.  Growth of Integrative Medicine at Leading Cancer Centers Between 2009 and 2016: A Systematic Analysis of NCI-Designated Comprehensive Cancer Center Websites.

Authors:  Hyeongjun Yun; Lingyun Sun; Jun J Mao
Journal:  J Natl Cancer Inst Monogr       Date:  2017-11-01

5.  Associations of Physical and Psychologic Symptom Burden in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Authors:  Daniel C McFarland; Kelly M Shaffer; Heather Polizzi; John Mascarenhas; Marina Kremyanskaya; Jimmie Holland; Ronald Hoffman
Journal:  Psychosomatics       Date:  2018-01-31       Impact factor: 2.386

Review 6.  Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions.

Authors:  Prathibha Surapaneni; Robyn M Scherber
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

7.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

8.  [Assessment of a brief fatigue inventory in patients with hematologic malignancies].

Authors:  Luz Alejandra Lorca; Cinara Sacomori; Bárbara Puga
Journal:  Rev Med Chil       Date:  2016-07       Impact factor: 0.553

Review 9.  Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.

Authors:  Deepa Rj Arachchillage; Mike Laffan
Journal:  Semin Thromb Hemost       Date:  2019-08-05       Impact factor: 4.180

10.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Mark Jones; Deanna Kornacki; Kang Sun; Hagop Kantarjian
Journal:  J Hematol Oncol       Date:  2017-02-22       Impact factor: 17.388

View more
  2 in total

1.  Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study.

Authors:  Hninyee Win; Samantha Russell; Betsy C Wertheim; Victoria Maizes; Robert Crocker; Audrey J Brooks; Ruben Mesa; Jennifer Huberty; Holly Geyer; Ryan Eckert; Ashley Larsen; Krisstina Gowin
Journal:  JMIR Form Res       Date:  2022-03-31

2.  Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.

Authors:  Blake T Langlais; Gina L Mazza; Heidi E Kosiorek; Jeanne Palmer; Ruben Mesa; Amylou C Dueck
Journal:  J Hematol       Date:  2021-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.